UPDATE 1-Long-delayed Merck osteoporosis drug meets goal in study
September 15, 2014 at 14:33 PM EDT
Sept 15 (Reuters) - Merck & Co on Monday said it expects next year to seek U.S. approval for its long-delayed experimental osteoporosis drug, odanacatib, after the once-weekly medicine met its primary goals in a late-stage trial.
